Zobrazeno 1 - 10
of 59
pro vyhledávání: '"Lauranne A A P Derikx"'
Autor:
Beatriz Gros, Hannah Ross, Maureen Nwabueze, Nathan Constantine-Cooke, Lauranne A. A. P. Derikx, Mathew Lyons, Claire O’Hare, Colin Noble, Ian D. Arnott, Gareth-Rhys Jones, Charlie W. Lees, Nikolas Plevris
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 17 (2024)
Background: Long-term vedolizumab (VDZ) outcomes in real-world cohorts have been largely limited to 1-year follow-up, with few bio-naïve patients or objective markers of inflammation assessed. Objectives: We aimed to assess factors affecting VDZ per
Externí odkaz:
https://doaj.org/article/10cbb49b972a4eeb8e99feb5cd69cbc9
Autor:
Natasja van de Pol, Qiuwei Pan, Lauranne A. A. P. Derikx, Linda Bakker, C. Janneke van der Woude, Annemarie C. de Vries
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 16 (2023)
Background: Patients with inflammatory bowel disease (IBD) have an attenuated serologic response to COVID-19 vaccination. It is unclear whether an impaired immune response in vaccinated IBD patients impacts the susceptibility to SARS-CoV-2 infection
Externí odkaz:
https://doaj.org/article/5e43a488fd9e4a968ac5e7726fbfb2e5
Autor:
Beatriz Gros, Nikolas Plevris, Nathan Constantine‐Cooke, Mathew Lyons, Claire O'Hare, Colin Noble, Ian D. Arnott, Gareth‐Rhys Jones, Charlie W. Lees, Lauranne A. A. P. Derikx
Publikováno v:
United European Gastroenterology Journal, 11, 2, pp. 179-188
United European Gastroenterology Journal, 11, 179-188
United European Gastroenterology Journal, 11, 179-188
Contains fulltext : 291530.pdf (Publisher’s version ) (Open Access) BACKGROUND: Switching from originator infliximab (IFX) to biosimilar IFX is effective and safe. However, data on multiple switching are scarce. The Edinburgh inflammatory bowel dis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bfde6d1e9bca75e18790e9134a86c06b
Autor:
Mathew Lyons, Lauranne A. A. P. Derikx, James Fulforth, Sophie McCall, Nikolas Plevris, Philip W. Jenkinson, Kathryn Kirkwood, Spyros Siakavellas, Laura Lucaciu, Nathan Constantine‐Cooke, Ian D. Arnott, Paul Henderson, Richard K. Russell, David C. Wilson, Charlie W. Lees, Gareth‐Rhys Jones
Publikováno v:
Alimentary Pharmacology & Therapeutics, 56, 1, pp. 67-76
Lyons, M, Derikx, L A A P, Fulforth, J, Mccall, S, Plevris, N, Jenkinson, P W, Kirkwood, K, Siakavellas, S, Lucaciu, L, Constantine-cooke, N, Arnott, I D, Henderson, P, Russell, R K, Wilson, D C, Lees, C W & Jones, G 2022, ' Patterns of emergency admission for IBD patients over the last 10 years in Lothian, Scotland: A retrospective prevalent cohort analysis ', Alimentary Pharmacology and Therapeutics . https://doi.org/10.1111/apt.16867
Alimentary Pharmacology & Therapeutics, 56, 67-76
Lyons, M, Derikx, L A A P, Fulforth, J, Mccall, S, Plevris, N, Jenkinson, P W, Kirkwood, K, Siakavellas, S, Lucaciu, L, Constantine-cooke, N, Arnott, I D, Henderson, P, Russell, R K, Wilson, D C, Lees, C W & Jones, G 2022, ' Patterns of emergency admission for IBD patients over the last 10 years in Lothian, Scotland: A retrospective prevalent cohort analysis ', Alimentary Pharmacology and Therapeutics . https://doi.org/10.1111/apt.16867
Alimentary Pharmacology & Therapeutics, 56, 67-76
Background and Aims:The incidence of paediatric-onset inflammatory bowel disease (PIBD) continues to rise globally. We aimed to determine whether mode of delivery, gestational age at birth, or type of infant feeding contribute to the development of P
Autor:
Edo H J Savelkoul, Pepijn W A Thomas, Lauranne A A P Derikx, Nathan den Broeder, Tessa E H Römkens, Frank Hoentjen
Publikováno v:
Inflammatory bowel diseases.
Background Loss of response to infliximab or adalimumab in ulcerative colitis occurs frequently, and dose escalation may aid in regaining clinical benefit. This study aimed to systematically assess the annual loss of response and dose escalation rate
Autor:
Laura Kirckpatrick, Caitlin S Rees, Lauranne A A P Derikx, Claire O'Hare, Charlie W. Lees, Nikolas Plevris, Philip Jenkinson, S Siakavellas, Nathan Constantine-Cooke, Laura Lucaciu, Gareth-Rhys Jones, Heather W Dolby, Lynne M Merchant, Ian D. Arnott, Colin L. Noble, Shanna Su, Mathew Lyons
Publikováno v:
Journal of Crohn's and Colitis, 15, 2011-2021
Journal of Crohn's & Colitis
Journal of Crohn's and Colitis, 15, 12, pp. 2011-2021
Journal of Crohn's & Colitis
Journal of Crohn's and Colitis, 15, 12, pp. 2011-2021
Background and Aims Multiple adalimumab [ADA] biosimilars are now approved for use in inflammatory bowel disease [IBD]; however, effectiveness and safety data remain scarce. We aimed to investigate long-term outcomes of the ADA biosimilar SB5 in IBD
Autor:
Stefano Festa, Giulia Zerboni, Lauranne A A P Derikx, Davide Giuseppe Ribaldone, Gabriele Dragoni, Christianne Buskens, Els Nieveen van Dijkum, Daniela Pugliese, Francesco Panzuto, Iwona Krela-Kaźmierczak, Hilla Reiss Mintz, Ariella Bar-Gil Shitrit, Marìa Chaparro, Javier P Gisbert, Uri Kopylov, Niels Teich, Elez Vainer, Iris Nagtegaal, Frank Hoentjen, Maria Jose Garcia, Rafal Filip, Kalliopi Foteinogiannopoulou, Ioannis E Koutroubakis, Marjorie Argollo, Roy L J van Wanrooij, Hendrik Laja, Triana Lobaton, Marie Truyens, Tamas Molnar, Edoardo Savarino, Annalisa Aratari, Claudio Papi, Idan Goren
Publikováno v:
Journal of Crohn's & colitis, 16(6), 940-945. Elsevier
Festa, S, Zerboni, G, Derikx, L A A P, Ribaldone, D G, Dragoni, G, Buskens, C, van Dijkum, E N, Pugliese, D, Panzuto, F, Krela-Kaźmierczak, I, Mintz, H R, Shitrit, A B-G, Chaparro, M, Gisbert, J P, Kopylov, U, Teich, N, Vainer, E, Nagtegaal, I, Hoentjen, F, Garcia, M J, Filip, R, Foteinogiannopoulou, K, Koutroubakis, I E, Argollo, M, van Wanrooij, R L J, Laja, H, Lobaton, T, Truyens, M, Molnar, T, Savarino, E, Aratari, A, Papi, C & Goren, I 2022, ' Gastroenteropancreatic Neuroendocrine Neoplasms in Patients with Inflammatory Bowel Disease : An ECCO CONFER Multicentre Case Series ', Journal of Crohn's & colitis, vol. 16, no. 6, pp. 940-945 . https://doi.org/10.1093/ecco-jcc/jjab217
Journal of Crohn's and Colitis, 16, 6, pp. 940-945
Journal of Crohn's and Colitis, 16, 940-945
Festa, S, Zerboni, G, Derikx, L A A P, Ribaldone, D G, Dragoni, G, Buskens, C, van Dijkum, E N, Pugliese, D, Panzuto, F, Krela-Kaźmierczak, I, Mintz, H R, Shitrit, A B-G, Chaparro, M, Gisbert, J P, Kopylov, U, Teich, N, Vainer, E, Nagtegaal, I, Hoentjen, F, Garcia, M J, Filip, R, Foteinogiannopoulou, K, Koutroubakis, I E, Argollo, M, van Wanrooij, R L J, Laja, H, Lobaton, T, Truyens, M, Molnar, T, Savarino, E, Aratari, A, Papi, C & Goren, I 2022, ' Gastroenteropancreatic Neuroendocrine Neoplasms in Patients with Inflammatory Bowel Disease : An ECCO CONFER Multicentre Case Series ', Journal of Crohn's & colitis, vol. 16, no. 6, pp. 940-945 . https://doi.org/10.1093/ecco-jcc/jjab217
Journal of Crohn's and Colitis, 16, 6, pp. 940-945
Journal of Crohn's and Colitis, 16, 940-945
Background Gastroenteropancreatic neuroendocrine neoplasms [GEP-NENs] have rarely been reported in association with inflammatory bowel diseases [IBDs]. Methods An ECCO COllaborative Network For Exceptionally Rare case reports project [ECCO-CONFER] co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d72170d27eb56f218b932b74b05aa0ae
https://doi.org/10.1093/ecco-jcc/jjab217
https://doi.org/10.1093/ecco-jcc/jjab217
Autor:
Claire Bewshea, James R Goodhand, Peter Kelleher, Nick Powell, Rachel L Griffiths, Nicholas A. Kennedy, Philip J Smith, Shaji Sebastian, Arkir Zehra, Bessie Cipriano, Desmond Chee, Louise Greathead, Benjamin Hamilton, Simeng Lin, Rachel Nice, Lauranne A A P Derikx, Neil Chanchlani, Hajir Ibraheim, Peter M. Irving, Klaartje Kok, Charlie W. Lees, Jonathan Macdonald, Timothy J. McDonald, Allan Dunlop, Tariq Ahmad
Publikováno v:
Journal of Crohn's and Colitis, 16, 3, pp. 389-397
Journal of Crohn's & Colitis
Journal of Crohn's and Colitis, 16, 389-397
Chanchlani, N, Lin, S, Chee, D, Hamilton, B, Nice, R, Arkir, Z, Bewshea, C, Cipriano, B, Derikx, L A A P, Dunlop, A, Greathead, L, Griffiths, R L, Ibraheim, H, Kelleher, P, Kok, K B, Lees, C W, MacDonald, J, Sebastian, S, Smith, P J, McDonald, T J, Irving, P M, Powell, N, Kennedy, N A, Goodhand, J R & Ahmad, T 2022, ' Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses : Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients ', Journal of Crohn's & colitis, vol. 16, no. 3, pp. 389-397 . https://doi.org/10.1093/ecco-jcc/jjab153
Journal of Crohn's & Colitis
Journal of Crohn's and Colitis, 16, 389-397
Chanchlani, N, Lin, S, Chee, D, Hamilton, B, Nice, R, Arkir, Z, Bewshea, C, Cipriano, B, Derikx, L A A P, Dunlop, A, Greathead, L, Griffiths, R L, Ibraheim, H, Kelleher, P, Kok, K B, Lees, C W, MacDonald, J, Sebastian, S, Smith, P J, McDonald, T J, Irving, P M, Powell, N, Kennedy, N A, Goodhand, J R & Ahmad, T 2022, ' Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses : Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients ', Journal of Crohn's & colitis, vol. 16, no. 3, pp. 389-397 . https://doi.org/10.1093/ecco-jcc/jjab153
Background and Aims Infliximab attenuates serological responses to SARS-CoV-2 infection. Whether this is a class effect, or if anti-tumour necrosis factor [anti-TNF] level influences serological responses, remains unknown. Methods Seroprevalence and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c08447d7329ab51228946a10f8ee899
Autor:
Michiel E. de Jong, Iris D. Nagtegaal, Shoko Vos, Rachel S. van der Post, Yasmijn van Herwaarden, Lauranne A. A. P. Derikx, Frank Hoentjen
Publikováno v:
Digestive Diseases and Sciences, 67, 12, pp. 5647-5656
Digestive Diseases and Sciences, 67, 5647-5656
Digestive Diseases and Sciences, 67, 5647-5656
Contains fulltext : 288024.pdf (Publisher’s version ) (Open Access) BACKGROUND: The impact of serrated polyps on the advanced colorectal neoplasia (CRN) risk in inflammatory bowel disease (IBD) patients is unknown. Serrated polyps are histologicall
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97061b748507cf6e448f1924fcfed8a2
https://repository.ubn.ru.nl/handle/2066/288024
https://repository.ubn.ru.nl/handle/2066/288024
Autor:
Tim van den Heuvel, Frank Hoentjen, Robert P. Takes, Carla M.L. van Herpen, Loes H C Nissen, Willem J. G. Melchers, Steffi E. M. van de Ven, Iris D. Nagtegaal, Lauranne A A P Derikx, Marieke Pierik, Rob H.A. Verhoeven
Publikováno v:
Inflammatory Bowel Diseases, 26(7), 1060-1067. Oxford University Press
Inflammatory Bowel Diseases, 26, 1060-1067
Inflammatory Bowel Diseases, 26(7), 1060-1067. LIPPINCOTT WILLIAMS & WILKINS
van de Ven, S E M, Derikx, L A A P, Nagtegaal, I D, van Herpen, C M, Takes, R P, Melchers, W J G, Pierik, M, van den Heuvel, T, Verhoeven, R H A, Hoentjen, F & Nissen, L H C 2020, ' Laryngeal Carcinoma in Patients with Inflammatory Bowel Disease: Clinical Outcomes and Risk Factors ', Inflammatory Bowel Diseases, vol. 26, no. 7, pp. 1060-1067 . https://doi.org/10.1093/ibd/izz210
Inflammatory Bowel Diseases, 26(7), 1060-1067. John Wiley and Sons Inc.
Inflammatory Bowel Diseases
Inflammatory Bowel Diseases, 26, 7, pp. 1060-1067
Inflammatory Bowel Diseases, 26, 1060-1067
Inflammatory Bowel Diseases, 26(7), 1060-1067. LIPPINCOTT WILLIAMS & WILKINS
van de Ven, S E M, Derikx, L A A P, Nagtegaal, I D, van Herpen, C M, Takes, R P, Melchers, W J G, Pierik, M, van den Heuvel, T, Verhoeven, R H A, Hoentjen, F & Nissen, L H C 2020, ' Laryngeal Carcinoma in Patients with Inflammatory Bowel Disease: Clinical Outcomes and Risk Factors ', Inflammatory Bowel Diseases, vol. 26, no. 7, pp. 1060-1067 . https://doi.org/10.1093/ibd/izz210
Inflammatory Bowel Diseases, 26(7), 1060-1067. John Wiley and Sons Inc.
Inflammatory Bowel Diseases
Inflammatory Bowel Diseases, 26, 7, pp. 1060-1067
Background Inflammatory bowel disease (IBD) patients are at increased risk for developing extra-intestinal malignancies, mainly due to immunosuppressive medication. The risk of developing head and neck cancer in immunosuppressed transplant patients i